Disease

Anhedonia

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 1 TRIAL

Psilocybin as a Novel Therapy for Residual Anhedonia

ClinicalTrials.gov

Phase 1 trial with planned enrollment and no results reported; registry record only describes study design and intended outcomes.

PreliminaryAnhedonia NCT07607938 Psilocybin

Reported

Planned enrollment90

Study phasePhase 1

Psilocybin dose25 mg

AUG 12, 2026 · INTERVENTIONAL STUDY

Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

ClinicalTrials.gov

This is a completed feasibility/optimization trial with no results posted; it uses a micro-randomized design to test engagement with a digital intervention component, not a clinical outcome.

PreliminaryAnhedonia Ksana Health Mental Health Disorder

Reported

Sample size24

Study duration4 weeks

Primary outcome measure 1Proximal engagement with ViraBrite, 24 hours

AUG 12, 2026 · INTERVENTIONAL STUDY

A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

ClinicalTrials.gov

This is a recruiting trial registration with no results reported; it describes planned enrollment and outcome measures only, making it an early-phase implementation study without efficacy data.

PreliminaryViraSafe: Treatment pushes Anhedonia Ksana Health

Reported

Estimated enrollment100

Primary outcome measure 1Proximal Engagement, 24 hours

Primary outcome measure 2Engagement with the apps, 3 months